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Direct-to-Consumer Marketing of Predictive
Medical Genetic Tests: Assessment of Current
Practices and Policy Recommendations
Yuping Liu and Yvette E. Pearson
This research reviews the current state of affairs in the fast-growing area of direct-to-consumer
marketing of genetic tests. The authors identify the unique nature of genetic tests and the ensuing
consumer vulnerability. They also present a comprehensive examination of the current legal
environment and an empirical analysis of genetic testing companies' online marketing practices. On
the basis of the analysis and review, they make a set of policy recommendations that consists of
consumer education, physician intervention and education, and direct regulation of marketing
activities, especially as they relate to the online medium.
Keywords: genetic testing, direct-to-consumer marketing, public policy, health care, Internet marketing

W

ith the completion of the Human Genome Project in
April 2003, medical genetic tests have become
more popular and have received a lot of media
attention. Currently, genetic tests for more than 1200 diseases are available to consumers (Javitt 2007), and this
number is likely to grow as additional disease-related genes
are identified. Rapid developments in genetics have led to
the quick growth of companies that market predictive
genetic tests and have spawned a profitable marketplace
expected to be worth $12.5 billion by 2009 (Alsever et al.
2006). According to its annual reports, Myriad Genetics
(2007), a leading marketer of medical genetic tests, experienced a growth of 44% as its molecular diagnostic test revenues increased from $100.6 million in 2006 to $145.3 million in 2007.
Although genetic testing has traditionally been available
to patients through their physicians, some companies have
begun direct-to-consumer (DTC) marketing of genetic tests
through the Internet or retail pharmacies. Some of these
companies market at-home genetic tests that can be conducted by simply swabbing inside the consumer's cheek.
This direct access to genetic tests offers consumers potential benefits, such as lower cost, more privacy with testing,

and increased awareness of genetic diseases. According to a
Harris Interactive poll (Taylor 2002), more than two-thirds
of adults surveyed were willing to undergo reasonably
priced genetic tests, and nearly half claimed that they would
ask for a genetic test even if nothing could be done to prevent or treat the target disease.
The growing DTC marketing of genetic tests combined
with heightened public interest suggests a need for more
public policy attention to this area. Currently, genetic testing services are not regulated consistently across the United
States, and existing federal regulations are minimal and
often confusing or ineffective insofar as they fail to better
inform or protect prospective consumers of genetic testing
services. Although some states allow only physicians to
order genetic tests, such restrictions are inconsistent across
states and are unlikely to affect online sales of genetic testing services because the authority of individual states does
not clearly extend into the online environment (Genetics
and Public Policy Center [GPPC] 2007c). There are also
questions about the clinical value of many genetic tests
(Gollust, Wilfond, and Hull 2003). Repeated calls to the
Centers for Medicare and Medicaid Services (CMS) and the
Food and Drug Administration (FDA) to improve regulation and oversight of genetic testing service providers have
been largely ignored. A recently released report by the
GPPC (see Javitt and Hudson 2006b) further confirms the
failure in oversight of genetic testing laboratories and the
need for vast improvements in the current regulatory
climate.
As we discuss subsequently, the combination of consumer ignorance, scant government regulation, aggressive
marketing practices, and the often overzealous media attention to genetic testing is a recipe for harm to individual consumers and public health. Although the probable negative
outcomes of DTC sales of genetic testing services are not
yet fully understood, problems with DTC marketing of
pharmaceutical drugs suggest the need for careful scrutiny
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of DTC marketing of genetic tests. Some researchers have
documented consumers' misconceptions about government
oversight and the validity of information presented in
advertisements (Wilkes, Bell, and Kravitz 2000). Others
have noted consumers' inability to comprehend the content
of drug advertisements (Weissman et al. 2004; Wilkes,
Bell, and Kravitz 2000) or to determine accurately whether
a particular drug is appropriate (Lexchin and Mintzes
2002). 1 Given the greater complexity of genetic information, consumers' failure to understand and properly use
DTC information can result in undesirable outcomes, such
as the use of an unnecessary or a low-quality test, needless
anxiety about test results, a false sense of security or doom,
harmful health and lifestyle choices, and inappropriate use
of health care services (Hudson et al. 2007). Thus, it is
important for marketing researchers, bioethicists, and those
working in the field of business ethics to reflect carefully on
DTC marketing practices and the context in which they
occur so that harm to consumers and public health can be
avoided.
To this end, this research assesses the current state of
DTC marketing of genetic tests and services. As far as we
know, this is the first comprehensive examination of the
topic in the marketing field. In our analysis, we evaluate
both business practices and government regulation of such
practices. This includes an empirical examination of DTC
marketing of genetic tests on the Internet, currently a major
medium for marketing activities in this area. Through such
analyses, we identify the potential benefits and problems
with DTC sales of genetic testing services. Finally, we
formulate a set of ethically sound public policy recommendations in this area. We begin with a brief description
of genetic tests.

A Primer on Genetic Testing
A gene is a sequence of deoxyribonucleic acid (DNA) that
codes for a specific function. Most genes provide instructions for the creation of proteins, which are sometimes
called the "building blocks of life." A "permanent structural
alteration in DNA" can occur, which is called a mutation
(see http://www.genome.gov). Although some mutations
have no effect, others contribute to impaired functioning of
the organism. For example, a deletion of part of the DNA
sequence in BRCAl, a tumor-suppressor gene, is a risk factor for increased susceptibility to a certain type of breast or
ovarian cancer. Genetic tests aim to identify the presence of
such mutations. In this research, we focus on one class of
genetic tests-namely, predictive genetic tests, which
include both tests that determine whether an individual is a
carrier who can pass a gene to the offspring and tests that
assess whether the individual him- or herself has an
increased susceptibility to a disease.
Ideally, a genetic test should be analytically valid. Two
components of analytical validity are sensitivity, which
refers to how often a test is positive when the mutation is
present, and specificity, which refers to the frequency of a
!Note that diverse opinions exist on the effects of OTC marketing of
prescription drugs and that not everyone believes it is harmful. For a
review of arguments on both sides, see Auton (2004) and Lexchin and
Mintzes (2002).

negative result when the mutation is absent. Because analytical validity alone does not guarantee that the test will be
valuable for patient management, it is also important to
consider the value of a test in the clinical setting (i.e., clinical validity and utility). A gap between analytical and clinical validity occurs if the detection of a mutation does not
correspond to symptoms observed in patients.
A common misunderstanding about predictive genetic
testing is that it provides definite knowledge of the future.
Although there are some rare diseases (e.g., Huntington's
disease) for which having the gene means that the person
will definitely get the disease, most diseases, including
more common afflictions, such as cancers and diabetes, do
not follow this straightforward pattern. Because many diseases are caused by gene-gene or gene-environment interaction, a genetic mutation alone may be neither necessary
nor sufficient for the manifestation of a disease. As a result,
knowledge that a person carries a particular mutation is
often of limited value. Contrary to the prevalent false
assumption of genetic determinism-the belief that future
health status is determined entirely by genetic makeuphaving a mutation does not guarantee that a person will get
a disease associated with a particular mutation.
Both analytical and clinical validity can diverge from
clinical utility if there are no preventive or curative measures for patients who carry what is believed to be a harmful mutation. Although the negative effects of some diseases (e.g., Phenylketonuria) are currently preventable with
knowledge that a person carries a "bad" gene, the medical
profession lacks not only preventive or curative measures
but also treatments for many genetic diseases. However, the
widespread publicity of the Human Genome Project has
caused excessive optimism regarding the probability and
proximity of procuring clinical benefits from emerging
genetic technologies (Burke 2004; Conrad 2002). As Burke
(2004, p. 9) points out, "the predictive power of genetic
information is routinely overestimated, and testing possibilities that are no more than research ideas are presented
as imminently available." Although the results of some
genetic tests may be valuable to the patient, there is good
reason to be cautious when making claims regarding the
ability of genetic tests to contribute to more effective clinical care or improved patient health.

OTC Marketing of Genetic Tests:
Promises and Perils
Emerging Trends in Genetic Testing
Genetic testing is not new, but the application of genetic
tests has been changing in recent years. First, the way
genetic testing is done is changing. In the past, physicians
would order genetic tests as part of a broader panel of diagnostic tests and procedures or as part of a screening program. Although genetic testing is still done mainly through
physicians, consumers can now undergo genetic testing at
home. A typical at-home genetic test entails consumers collecting their own sample, sending it to a lab for analysis,
and then receiving the results in the mail or through the
Internet. An increasing number of genetic tests are offered
through such means, and companies selling these tests have
stepped up their DTC marketing efforts.

Journal of Public Policy & Marketing

Second, the rationale for undergoing genetic tests is also
shifting. Until recently, genetic testing has been diagnostic
and restricted mainly to prenatal and newborn testing (Taylor, Edwards, and Ku 2006). Increasingly, however, genetic
testing is motivated by a desire to determine what might be
rather than attempting to confirm a tentative diagnosis of a
genetic disease. An asymptomatic adult may request a
genetic test because his or her family history indicates
affliction with a disease, or the person may simply be curious about whether he or she carries any genes that have
been linked with an increased risk of a disease.
Finally, genetic testing is also rapidly broadening beyond
rare, single-gene disorders that have a simple inheritance
pattern (e.g., Huntington's disease). An increasing number
of predictive genetic tests now target common diseases
(e.g., cancers, cardiovascular diseases) that are more genetically complex. These tests ostensibly allow patients to learn
whether they carry genes associated with increased susceptibility to common diseases. This scenario poses new problems in terms of interpretation and clinical application of
results.

Potential Benefits of OTC Marketing of and
Access to Genetic Tests
Although there are legitimate concerns about the validity
and value of many genetic tests, DTC marketing of and
access to genetic tests may benefit some consumers. First,
DTC marketing can raise awareness of genetic diseases and
the availability of genetic tests, and this may encourage
patients to visit a health care professional to learn more
about a genetic test or hereditary disease. In her discussion
of DTC marketing of prescription drugs, Kelly (2004, pp.
247--48, n. 7) cites a study that showed that nearly twothirds of "physicians serving a predominantly [African
American] population reported that patients have come in
solely because of a DTC ad." Second, Racine, Van der
Loos, and Illes (2007) note that people who have or suspect
they have a stigmatized illness (e.g., herpes, depression,
incontinence) are more reluctant to seek help through traditional means because, for example, even visiting a psychiatrist suggests that a person has a mental illness. In the realm
of genetic testing, we can imagine that a person who suspects that he or she has a hereditary form of a stigmatized
illness might prefer to avoid going to a physician or genetic
counselor to conceal his or her quest for personal genetic
information. Because DTC access to genetic tests bypasses
the traditional health care hierarchy, it may offer consumers
greater privacy and thus reduce such psychological barriers.
Relatedly, with fewer people sharing the information, DTC
genetic tests may also keep genetic information out of the
hands of those who might use it to the detriment of the individual tested.

Consumer Vulnerability and Its Consequences
The realization of potential benefits provided by DTC marketing of and access to genetic tests is context dependent. A
genetic test is a unique product in that it involves complex
information and requires a high level of knowledge for the
product to be purchased and "consumed" properly. Existing
research has shown that even physicians are often illequipped to provide genetic services (e.g., National Insti-
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tutes of Health Task Force on Genetic Testing 1997; Taylor, Edwards, and Ku 2006). Average consumers are in a
worse epistemic position, and most of them are unable to
protect themselves adequately or to make genuinely
informed decisions regarding genetic tests. Because consumers are encouraged to bypass rather than consult with
genetic counselors or other relevant professionals, DTC
marketing of genetic tests remains ethically questionable.
For many consumers and physicians (Goddard et al.
2007), the primary sources of information about genetics
are the popular media and genetic test vendors, both of
which can be misleading. The popular press is often driven
by the enthusiasm and hype about discoveries of "disease
genes." As a result, the public often hears a lot about exciting discoveries and little, if anything, about disconfirming
evidence or failures to replicate study results connecting
genes to traits or maladies (Conrad 2002). Because the
"news media are the major avenue by which information
about genetics enters the culture," failure to properly report
disconfirmations can lead to obsolete or false information
becoming "fossilized in the culture" (Conrad 2002, p. 75).
Skepticism is also warranted about the objectivity and
scientific verifiability of information provided by marketers
of genetic tests, given their dominantly for-profit motive.
The limitations of marketer-supplied information have been
well documented in the literature on DTC advertising of
prescription drugs (Macias and Lewis 2005; Main, Argo,
and Ruhmann 2004; Wolfe 2002). Given the weaker regulatory oversight of genetic testing, information supplied by
marketers of genetic tests is likely to be even more problematic. Consistent with this view, research has shown that
physicians' use of pharmaceutical companies as a frequent
source of information is a negative indicator of their knowledge of genetics (Hofman et al. 1993). Although the current
situation may have changed from the much earlier study,
our own analysis of commercial genetic testing Web sites,
which we report on in greater detail subsequently, confirms
the bias in the information provided by online genetic test
marketers. Such findings raise serious doubt that consumers
will be properly educated through existing marketing
materials.
Although there are good information sources on genetics,
consumers may be unable to distinguish between accurate
and inaccurate sources or identify bias. To make matters
worse, although physicians often realize their own knowledge deficits (Hofman et al. 1993), consumers may be
unaware of their own ignorance of genetics and, therefore,
unlikely to seek information. Prior research has found that
such overconfidence is prevalent among consumers and that
it leads to suboptimal search and purchase decisions (Alba
and Hutchinson 2000).
Consumers' vulnerability in the decision-making process
regarding genetic tests can endanger their long-term health
and welfare (Cella et al. 2002; Lee and Brennan 2002).
Those who are neither aware of nor warned about the risk
of false positives and false negatives are likely to overestimate the significance of test results. This can induce
unfounded anxiety and fear or a false sense of security in
test takers. People genetically related to someone who
undergoes genetic testing may also be affected nonvoluntarily by test results. Although there is some debate about
whether and to what extent genetic test results affect patient
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behavior, a recently released statement from the American
Society of Human Genetics warns of the possibility of consumers making irrevocable decisions based on these results
(Hudson et al. 2007). In the news, there have been multiple
accounts of people making life-altering decisions based on
genetic test results (usually combined with knowledge of
their family history relative to the disease in question). For
example, some women have reportedly had their breasts
and ovaries removed when a genetic test revealed that they
carried a mutation of the BRCAl (or BRCA2) gene (Herel
2002). Burke and colleagues (2002) also note that a fatalistic attitude may result from knowledge of personal genetic
risk. Along similar lines, De Melo-Martin (2006b) argues
that relying on genetic tests as a means to ameliorate human
suffering might prevent people from making necessary
changes to the social contexts and institutions that contribute to the perpetuation of disease and disability. From a
social welfare perspective, undergoing unnecessary testing
and subsequently seeking remedial measures can overburden the health care system and divert precious resources
from practices and procedures that have a much higher clinical value.

Current Regulation of Genetic Tests
The recently passed FDA Amendments Act of 2007, which
requires the Secretary's Advisory Committee on Genetics,
Health, and Society to complete an assessment of the quality and safety of genetic tests, is just one manifestation of
justified concern about the current lack of regulation of
genetic testing services. However, the GPPC notes that the
lack of regulation and oversight is not due to a shortage of
recommendations from task forces or advisory committees
(GPPC 2007a; Javitt and Hudson 2006b). In particular, over
a decade ago, the Institute of Medicine conducted an
inquiry that addressed precisely these issues and made recommendations. Other large-scale studies were conducted by
the 1995 National Institutes of Health Task Force on
Genetic Testing and the 2000 Secretary's Advisory Council
on Genetic Testing. Researchers have explained repeatedly
that policy makers and public agencies should implement
the recommendations that have been put forth (e.g., Javitt
and Hudson 2006a, b). Thus far, however, policy makers,
including legislators, are either unsure of how to proceed or
unwilling to create and enforce much needed regulations.
Currently, certain parts of the genetic testing process are
governed by a few federal regulations that were not formulated specifically for genetic tests. One such regulation is
the Clinical Laboratories Improvement Amendments
(CLIA) of 1988, which is administered by the CMS. The
goal of the CLIA is to "ensure quality laboratory testing."
However, the CUA does not "address the inherent safety
and effectiveness" of genetic tests (Andrews et al. 1994,
p. 136), and it does not regulate laboratories' claims about
such tests (Hudson et al. 2007). Until August 2006, the
CMS appeared to be moving toward developing a specialty
area for genetic testing, but it suddenly decided that it was
not vital to do so (Javitt and Hudson 2006b). The absence
of a specialty area in genetics threatens both the analytic
and the clinical validity of genetic tests. Although the CLIA
addresses only analytic validity, that analytic validity is a
necessary but not sufficient condition for clinical validity or

utility means that knowledge of a test's analytic validity
would clarify which tests are definitely not going to be
clinically valuable.
In addition to the CLIA, the FDA provides oversight over
some genetic testing services, mainly in the area of premarket approval, but significant ambiguity remains about the
FDA's regulatory authority over genetic testing services.
Only genetic tests marketed as kits are under direct FDA
regulation as in vitro diagnostic devices, but because most
genetic tests are not marketed as kits, they can sidestep
FDA approval. Javitt (2007) notes that the FDA has
approved only eight genetic test kits, which indicates a preference on the part of test manufacturers to evade regulation.
In addition to regulating in vitro diagnostic devices, the
FDA also regulates "analyte-specific reagents," which it
classified as medical devices in 1997. Analyte-specific
reagents are the active ingredients in laboratory-developed
tests, which, unlike test kits, do not include instructions and
information regarding the purpose and proper use of a test;
instead, the labs themselves determine the composition and
application of tests (Javitt and Hudson 2006a). The FDA's
regulation of analyte-specific reagents restricts their sale to
labs, but it does not dictate their use in laboratorydeveloped tests.
Regulatory deficits become even more obvious with
DTC marketing of genetic tests. Neither the CMS nor the
FDA regulates the content of communications from genetic
testing companies to the public. Advertisements for genetic
tests are subject to the general principle of truthful advertising under Federal Trade Commission (FTC) regulations,
which requires claims in advertisements to be true and substantiated (FTC 1984a, b). However, given the complex
nature of genetic science and consumers' lack of knowledge
in this area, FTC regulations are likely to be inadequate to
oversee marketing activities in the genetic testing industry.
This contrasts with the FDA's regulation of prescription
drug advertising (21 CPR § 202.1), which treats prescription drugs as unique products and requires their advertisements to provide true and balanced information, including
mandatory disclosure of the drugs' harmful effects alongside information about benefits.
At the state level, regulation is mixed. A GPPC (2007c)
report indicated that there are no restrictions on DTC laboratory testing in 26 states and the District of Columbia.
Only 11 states explicitly prohibit DTC access to genetic
tests. In most states in which consumers are allowed direct
access to genetic tests, the law says nothing. The current
legislative silence leads to the assumption that DTC access
to genetic tests is permissible and even desirable, though
there is currently insufficient evidence to support such an
assumption.

Online OTC Marketing of Genetic Tests:
An Empirical Assessment
Overview
To further assess current DTC marketing practices, we
content-analyzed genetic testing companies' Web sites. Our
focus on the Internet was based on consumers' increasing
use of this medium to look for health information (Sewak et

Journal of Public Policy & Marketing

al. 2005; Waack, Ernst, and Graber 2004). Recent statistics
show that 84% of U.S. Internet users have searched for
health information online (Harris Interactive Inc. 2007), and
more than half of the searchers reported that their most
recent online search influenced how they cared for themselves or others (Fox 2006). Although large-scale advertising campaigns of genetic tests through the traditional media
(e.g., the fall 2007 campaign by Myriad Genetics; see
GPPC 2007b) are still rare, most genetic test marketers
have developed a Web presence. Corporate Web sites are
currently the main source of DTC marketing information
and thus form the target of our empirical analysis. Similar
to prior examinations of DTC advertising of prescription
drugs (Macias and Lewis 2005; Waack, Ernst, and Graber
2004), our purpose is to determine the extent to which
information provided by DTC marketing Web sites is
biased or incomplete and whether such information is
merely a persuasive ploy or a useful resource that helps
consumers make more informed decisions. By identifying
the problems in current practices, we hope to provide helpful input for public policy that can eventually address these
problems.

Methodology
Sample Identification
To identify the Web sites that market genetic tests, a trained
research assistant conducted searches using all major Internet search engines first in July 2006 and again in December
2007. Variations of keywords, such as "genetic tests" and
"genetic testing services," were used. Online directories
published by Yahoo and Google were also perused to identify relevant Web sites that might not have turned up during
the search process. Of all the Web sites found, we then
selected those that market predictive genetic testing services. We excluded information-only Web sites and Web
sites of companies based outside the United States, consistent with our focus on regulatory issues in the United
States. Because these classifications were fairly straightforward, we did not encounter any disagreement as to which
ones should be included. The final list consisted of 63 Web
sites, 46 of which had significant consumer-targeted content (see Table 1). Over five years, the number of DTC
genetic testing sites has increased significantly, almost
tripling the number of sites found in previous studies (Gollust, Wilfond, and Hull 2003; Williams-Jones 2003). This
shows the rapid growth of online DTC marketing by the
genetic testing industry. Some Web sites found in previous
searches no longer existed or had changed their corporate
identity by the time of our search, suggesting the volatile
nature of the marketplace.
The other 17 Web sites in our final list targeted mainly
health care professionals (see Table 2).2 We retained these
Web sites and analyzed them along with the DTC site
group. The rationale for such comparative analysis was
2We

made this distinction by considering the following: (1) clear statement of Web site targeting only physicians; (2) consistent referencing of
the reader as a health care professional (e.g., "your patients"); and (3) no
separate page, document, or section specifically for nonprofessionals. The
intercoder agreement was 95.0%. Disagreements between the two coders
were resolved through discussion.
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that, given the assumption, albeit problematic, that health
care professionals are likely to have a higher level of
"genetic literacy" than laypersons, it would be expected that
they are better able to process and evaluate information
(Alba and Hutchinson 1987), which may in tum motivate
marketers to provide higher-quality information. However,
our results cast doubt on some of these assumptions. In
addition to professional versus DTC Web sites, we compared the professional versus consumer sections within the
24 DTC Web sites that had significant materials for both
consumers and professionals.3 Because these sections
reside within the same Web sites, such an analysis can offer
an even more telling picture of the different ways marketers
may treat the two segments.

Content Coding and Data Analysis
Following recommended content analysis procedures
(Neuendorf 2002), our analysis was guided by a codebook,
which contained variables related to the availability and
quality of information and to the use of emotional appeals.
To develop information quality criteria, we examined prior
research on genetic testing (Gollust, Wilfond, and Hull
2003; McCabe and McCabe 2004; Shepperd et al. 2006)
and, more generally, on what is considered quality health
care information (Chamock et al. 1999; Entwhistle et al.
1996). We also drew from the field of DTC marketing of
prescription drugs (e.g., Main, Argo, and Ruhmann 2004;
Waack, Ernst, and Graber 2004; Woloshin et al. 2001). On
the basis of these sources, we examined the presence/
absence of the following in each Web site: (1) basic information on genetics, (2) probabilistic nature of genetics, (3)
balanced information (i.e., both pros and cons of genetic
testing), (4) alternatives to genetic testing, (5) privacy policy, and (6) scientific information for professionals. For the
use of emotional appeals, we studied six positive emotional
appeals (happiness/joy, warmth, pride, empowerment,
assurance/peace of mind, and relief) and four negative emotional appeals (fear, guilt/shame, regret, and sadness).
These emotional appeals were drawn from existing typologies of emotions (Bagozzi, Gopinath, and Nyer 1999; Roseman 1991) and from studies of emotional appeals in DTC
advertising (e.g., Main, Argo, and Ruhmann 2004; Wolfe
2002; Woloshin et al. 2001).
Two judges independently coded each Web site using the
codebook. The overall intercoder agreement was 93.3%,
the intercoder agreement for each codebook item appears
in Table 3. Disagreements between the two coders were
resolved through discussion. The coded data were then analyzed with SPSS. For the prevalence of a feature, we used
frequency analysis. To compare between Web sites and
between sections within the same DTC Web sites, we used
chi-square analysis. For the use of emotional appeals, we
also used t-tests to compare the total numbers of emotional

3This comparison applies only to the 24 DTC Web sites that had both a
consumer section and a professional section. One of the DTC Web sites,
CyGene Direct, requires that people log in to access professional information and is excluded from this analysis. We also note that certain features
(e.g., privacy policy) are sometimes available as general sections of a Web
site. In such cases, they are considered to belong to both the consumer section and the professional section.
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Table 1.

DTC Genetic Testing Web Sites

Tests Offered

Patient Direct
Order

Doctor
Intervention
Required

Comprehensive genetic profile

Yes

No

Alzheimer's disease

Yes

No

Pregnancy loss

No

Yes

Newborn screening for metabolic diseases

Yes

Yes

Center for Medical Genetics
(http://www.geneticstesting.com)

Cystic fibrosis, pregnancy loss, prenatal, TaySachs, Bloom syndrome, and others

Yes

No

Cincinnati Children's Hospital
(http://www.cincinnatichildrens.org/svc/
topics/genetics.htm)

Hearing loss, metabolism, mental retardation,
lysosomal storage disease, and others

No

Yes

Risk of heart attack and infertility due to caffeine
and wine intake

Yes

No

Osteoporosis, thrombosis, and others

Yes

No

DNA Direct
(http://genesanddrugs.dnadirect.com)

Breast and ovarian cancer, cystic fibrosis,
diabetes, and others

Yes

No

DNATraits (http://www.dnatraits.com)

Fragile X, clotting disorders, sickle-cell anemia,
and others
Down syndrome, metabolic diseases,
neurofibromatosis, and others

Yes

No

No

Yes

Preconception and prenatal

No

Yes

GeneCare Medical Genetics Center
(http://www.genecare.com/)

Cystic fibrosis, Tay-Sachs, hereditary
hemochromatosis, and others

No

Yes

Genelex (http://www.healthanddna.com/)

Nutrigenomics and pharmacogenetics

Yes

No

Oxidative stress, cardiovascular health, bone
health, metabolism problems, aging, skin health,
and nutrigenomics

Yes

No

Cystic fibrosis, Tay-Sachs, familial
dysautonomia, and others

No

Yes

Genova Diagnostics
(http://www.genovadiagnostics.com)

Cardiovascular health, osteoporosis, immune
system health, and others

No

Yes

Genzyme Genetics
(http://www.genzymegenetics.com/
default.asp)

Cystic fibrosis, fragile X, Down syndrome, and
others

No

Yes

Alzheimer's disease

Yes

No

Cystic fibrosis, fragile X, sickle-cell anemia, and
others

No

Yes

Company Name and Web Site Address
23andMe (http://www.23andme.com)
Alzheimer's Mirror (http://alzmirror.com)
Andrology Laboratory Services
(http://www.androlab.com)
Baylor Health Care System
(http://www.baylorhealth.com/medical
specialties/metabolic/newbomscreening.htm)

Consumer Genetics
(http://www.consumergenetics.com/)
Cygene Direct
(http://www.cygenedirect.com/default.html)

Emory University Genetics Clinic
(http://www.genetics.emory.edu/clinics.php)
GenAssist (http://www.genassist.com/)

GeneLink (http://www.genelink.info)

Genetics & IVF Institute
(http://www.givf.com)

Graceful Earth
(http://www.gracefulearth.com/)
Great Lakes Genetics
(http://www.genetest.com/)
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Continued

Patient Direct
Order

Doctor
Intervention
Required

Celiac disease, thrombosis, and hereditary
hemochromatosis

Yes

No

Cystic fibrosis

Yes

No

HIV/AIDS progression

Yes

No

Nutrigenomics

Yes

No

Breast cancer, cystic fibrosis, and others

No

Yes

Nutrigenomics and gum disease

Yes for Gensona/
no for PST

No for Gensona/
yes for PST

John Stoddard Cancer Center
(http://johnstoddardcancer.org/body .cfm?
id=l 1)

Breast cancer, ovarian cancer, colorectal
cancer, and related cancers

No

Yes

Kimball Genetics
(http://www.kimballgenetics.com/)

Broad beta disease, celiac disease, cystic
fibrosis, and others

Yes

Yes

LabCorp
(http://www.labcorp.com/genetics/index.html)

Prenatal

No

Yes

MarketAmerica
(https://www .marketamerica.com/corporate/
index.cfm ?action=services. wpGeneSNPinfo)

Nutrigenomics

Yes

No

Alzheimer's disease, thrombosis, osteoporosis,
and others

Yes

No

Breast cancer, ovarian cancer, colorectal
cancer, endometrial cancer, and melanoma

No

Yes

Cystic fibrosis, Tay-Sachs, Canavan disease,
and others

No

Yes

Newborn screening

Yes

Yes

PGx Health (http://www.pgxhealth.com/
genetictests/familion/)

Heart disease

No

Yes

Quest Diagnostics
(http://www.questdiagnostics.com/)

Breast cancer

No

Yes

Quixtar (http://www.quixtar.com/products/
product.aspx?itemno= 104009)

Heart disease

Yes

No

Salugen (http://www.salugen.com)

N utrigenomics

Yes

No

Sciona (http://www.mycellf.com)

Nutrigenomics

Yes

No

Prenatal

No

Yes

Cellular health

No

Yes

Company Name and Web Site Address

HealthCheckUSA
(http://www.healthcheckusa.com/)
Health Tests Direct (http://www.health-testsdirect.com)
HIVMirror (http://www.hivmirror.com/)
Holistic Heal (http://www.holisticheal.com)
InterGenetics Incorporated
(http://www.intergenetics.com/)
Interleukin Genetics (http://www.ilgenetics.com/)

MyGenome (http://www.mygenome.com/)

Myriad Genetic Laboratories
(http://www.myriadtests.com/)
NYU Human Genetics Program
(http://www.med.nyu.edu/pediatrics/genetics/)
Pediatrix (http://www.pediatrix.com/)

Signature Genomic Laboratories
(http://www.signaturegenomics.com)
Suracell (http://www.suracell.com)

Tests Offered
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Table 1.

Continued

Company Name and Web Site Address

Tests Offered

Patient Direct
Order

Doctor
Intervention
Required

University of California, San Diego Medical
Center (http://health.ucsd.edu/specialties/
medgenet/)

Angelman syndrome, Bloom syndrome, Canavan
disease, and others

No

Yes

University of Rochester Medical Center
(http://www.urmc.rochester.edu/genetics/)

Breast cancer, colon cancer, cystic fibrosis,
sickle-cell anemia, thalassemia, and other
hemoglobinopathies

No

Yes

Vanderbilt's Monroe Carell Jr. Children's
Hospital (http://vanderbiltchildrens.com/
interior.php?mid=l 78)

Newborn screening, prenatal

No

Yes

Vysis Aneuvysion (http://www.aneuvysion.com/)

Prenatal

No

Yes

Yale Cancer Center (http://www.
yalecancercenter.org/genetics/index.html)

Cancer

No

Yes

appeals used and the numbers of positive and negative
appeals used.

Results on Information Practices
A summary of results from the content analysis and a brief
description of each variable appear in Table 3. Of 46 DTC
Web sites, 43.5% allowed consumers to order directly from
the company. Another 10.9% allowed consumers to order
test kits directly but required doctor intervention to submit
samples for analysis or to obtain results. The remaining
Web sites allowed order placement and/or referral by a
health care professional only. Test cost information was
provided on half (52.2%) of the DTC Web sites. Some Web
sites allowed consumers to order test kits for free but did
not provide information on the cost of the sample analysis
and results reporting. We surmised that test kits received by
consumers would disclose cost information.

Basic Genetic Information
The complexity of genetic information makes it critical for
consumers to receive proper education and assistance in
understanding such information (Gollust, Hull, and Wilfond
2002; kSERO Corporation 2003). We examined each Web
site for explanations of genetic terminology and of how
genes and genetic tests work. Of the DTC Web sites, 47.8%
offered such information, often in the form of a glossary or
a health library. Another 17.4% did not offer basic genetic
information but provided links to other Weh sites where
consumers could find such information. Surprisingly, the
professional Web site group did much worse (x 2 =5.35, p =
.02), with only 17.6% of the Web sites providing basic
genetic information and another 17 .6% offering links to
such information. We observed similar differences between
professional and consumer sections within a Web site, with
58.3% providing basic genetic information in the consumer
section versus only 33.3% in the professional section.
Another 16.7% of the consumer sections provided links to
basic genetic information, whereas only 12.5% of the professional sections did so.

Probabilistic Nature of Genetics
As we noted previously, carrying a particular mutation does
not always entail affliction with the related disease. Consumers who undergo genetic testing should be aware of this
to avoid unnecessary stress caused by test results that indicate the presence of a mutation. For some consumers,
knowing the probabilistic nature of genetics may also make
them decide against taking genetic tests and avoid anxiety.
Of the DTC Web sites, 45.7% provided information on
inheritance patterns and the probability of getting a disease
if a person carries the mutation. For professional-oriented
Web sites, 47.1 % provided such information. There was no
significant difference between the consumer (58.3%) and
the professional (50.0%) sections within a Web site. Three
(6.5%) DTC Web sites contained statements and language
reflecting genetic determinism. Notably, all three of these
Web sites allowed consumers to order directly from them
without any doctor's intervention, thus leaving consumers
more susceptible to erroneous decisions that could negatively affect their health.
Pros and Cons of and Alternatives to Genetic Testing
Balanced information refers to information on both the
benefits and the risks of genetic testing. Of the 46 DTC
Web sites, only 15.2% discussed potential harmful effects
of genetic testing. The professional Web sites performed
equally poorly, with only 5.9% offering both pros and
cons.4 When we compared the consumer and professional
sections, 16.7% of the consumer sections discussed pros

"Closely related to the pros and cons of genetic testing is the possibility
of false positives and/or false negatives (i.e., clinical validity) of the tests
provided. Our analysis showed that only 26.1 % of the DTC Web sites provided specific false positive/negative rates, and 10.9% of the Web sites
mentioned the possibility of a false positive/negative, but they did not give
any rate. Professional Web sites performed similarly, with 35.3% offering
false positive/negative rates and another 17 .6% mentioning the possibility
of a false positive/negative without specific rates.
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Professional Genetic Testing Sites

Company Name and Web Site Address
Ambry Genetics (http://www.ambrygen.com)
Athena Diagnostics (http://www.athenadiagnostics.com)
Baylor Medical Genetics Lab (http://www.bcm.edu/geneticlabs/)
BRT Laboratories (http://www.rhlab.com/P53.html)
Case Western University Hospitals
(http://www.uhhospitals.org/case/OurServices/Centersand
Programs/GM/AddictionRecoveryServices/tabid/ 1196/Default.
aspx)
Duke Medical Genetics
(http://medgenetics.pediatrics.duke.edu/modules/services/
index.php?id=l)
Genedx (http://www.genedx.com)
Kennedy Krieger Institute Genetics Laboratories
(http://genetics.kennedykrieger.org)

Tests Offered
Cystic fibrosis, pancreatitis, diabetes, pulmonary diseases, and
others
Hearing loss, diabetes, obesity, and others
Cystic fibrosis, fragile X, osteoporosis, Huntington's disease,
prenatal, and others
Cancer tumor suppression
Cystic fibrosis, fragile X, hearing loss, and others

Neurofibromatosis, Down syndrome, fragile X, lysosomal
disorders, and others
Prenatal, skin disorders, and others
Peroxisomal disease, prenatal, Canavan disease, and others

LSU Health Sciences Center (http://www.lsuhsc.org)

Cancer, prenatal, and others

Molecular Diagnostics Laboratories (http://www.mdl-labs.com/)

Thrombosis

OHSU Cancer Genetics
(http://www.ohsu.edu/outreach/cdrc/clinical/portland/
genetics_cancer.html)
Prometheus (http://www.prometheuslabs.com/212.asp ?nav=products)

Cancer

Celiac disease, metabolism, lactose digestion

Robert Guthrie Genetics Lab (http://www.rgbgl.org)

Metabolism, lysosomal storage disease, muscle disease

Stanford Medical Genetics
(http://pediatrics genetics. stanford.edu/patient_care)

Down syndrome, neurology, metabolism, cancer, and prenatal

UMDNJ Institute of Genomic Medicine
(http://www. umdnj .edu/genesatwork/)
University of South Alabama Birth Medical Genetics
(http://www.southalabama.edu/genetics/bdgc_index.htm)
University of Washington Genetics Lab
(http://depts.washington.edu/labweb/Divisions/
Mo!Diag/Mo!DiagGen/index.htm)

and cons, whereas 25.0% of the professional sections
offered such information. This lack of evenhanded information contrasts sharply with the fair balance requirement
governing DTC advertising of prescription drugs, possibly
because of the aforementioned confusion over regulatory
oversight of genetic tests. Although genetic testing may not
cause the same side effects as prescription drugs, as we discussed previously, the potential negative financial and psychological effects of genetic testing can be equally severe
and far-reaching (Cella et al. 2002; Lee and Brennan 2002).
To exacerbate the lack of balanced information, only
15.2% of the DTC sites suggested viable alternative means
of predicting or diminishing the likelihood of being affected
by a hereditary condition, such as maintaining a healthful
lifestyle, relying on family history, or taking other non-

Prenatal, sickle-cell anemia, neurofibromatosis, and
neuromuscular diseases
Mental retardation, neurofibromatosis, Turner syndrome, Down
syndrome, fragile X, and others
Cystic fibrosis, hearing loss, fragile X, Factor V Leiden,
Huntington's disease, and others

gene-based tests. This absence is especially pronounced in
Web sites that allowed direct orders, with 95.0% missing
information about alternatives. Professional Web sites fared
no better, with only 11.8% mentioning alternatives to
genetic testing. We found a similarly low percentage
(8.3%) in the professional sections of DTC Web sites.
Without information about alternative approaches and
potential negative effects of genetic testing, these Web sites
effectively exaggerate the benefits of genetic testing and
encourage unnecessary testing.

Privacy Policy
The extensive implications of genetics for health care make
it critical to protect consumers' private information in this
area (Lerman and Shields 2004). Currently, consumer pri-
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Table 3.

Content Analysis Results Summary
Present in
Present in DTC Professional
Web Sites
Web Sites

Intercoder
Agreement

Coding Variable

Variable Description

Information
Basic genetic
information

Information on basic genetic terms and patterns of heritability
(e.g., a glossary of terms).

47.8%

17.6%

86.7%

Information about the probabilistic nature of genetics and
genetic tests (e.g., probability of getting a disease if a person
carries the mutation).

45.7%

47.1%

81.7%

States both pros and cons of the products/services offered.

15.2%

5.9%

96.7%

Alternative means of predicting or diminishing the likelihood of
being affected by a hereditary condition (e.g., a healthful
lifestyle and non-gene-based tests).

15.2%

11.8%

93.3%

Provision of a privacy policy stating the protection of patient
health information.

71.7%

52.9%

91.7%

Professional information to health care providers (e.g.,
scientific proof of test validity and reliability, disease
information).

54.3%

100%

95.0%

Portrays situations that represent a good feeling, immense
pleasure, and even ecstasy; a promise of happiness.

21.7%

0%

91.7%

Warmth

Portrays a positive warm and fuzzy feeling that is less intense
than happiness/joy.

60.9%

29.4%

90.0%

Pride

Portrays a strong sense of self-respect, dignity, and superiority.

4.3%

0%

96.7%

Empowerment

Reflects an enhanced sense of power; appeals to a consumer's
desire to be in control; it can apply to dealing with both
desirable and undesirable situations.

60.9%

11.8%

93.3%

Assurance/peace of
mind

Appeals to a sense of peace, knowing for certain of a positive
outcome.

34.8%

23.5%

90.0%

Relief

Portrays a sense of relaxation after removal of something
stressful; less outcome-related but rather the mere fact that "I
finally know."

26.1%

12.5%

90.0%

Fear

Portrays a negative, undesirable scenario that may happen in
order to arouse fear in the audience.

26.1%

5.9%

96.7%

Guilt/shame

Presents actual violation or a potential violation of the
consumer's internalized standard of proper behavior.

2.2%

5.9%

98.3%

Regret

Portrays a dissatisfactory choice when a better choice
is/was possible.

10.9%

0%

93.3%

Sadness

Portrays situations representing a downcast mood, unhappiness,
and, in the extreme form, grief.

4.3%

0%

98.3%

Probabilistic nature of
genetics

Pros and cons
Alternatives

Privacy policy

Scientific information
for health
professionals
Emotional Appeals
Happiness/joy

vacy in the health care industry is protected by the Health
Insurance Portability and Accountability Act (HIPAA) of
1996, though HIPAA compliance is likely to be limited and
varied among online vendors (Choy et al. 2001). Under
HIPAA, health care professionals cannot share a consumer's health information without the consumer's explicit
consent. Of the DTC Web sites, 71.7% claimed to follow

HIP AA guidelines and posted privacy statements pledging
confidential treatment and protection of consumer information. In comparison, 52.9% of the professional Web sites
had a privacy policy. This lower presence of privacy policy
may be due to the physician-patient confidentiality rule that
requires physicians to protect patient information. It is
worth noting that in May 2008, the Genetic Information
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Nondiscrimination Act was signed into law, with the aim
to prevent employers and insurance companies from using
genetic information to the detriment of individuals.
Although the act is likely to alleviate prospective consumers' fears, how it will affect genetic testing practices
remains to be seen.

Scientific Information for Health Care Professionals
To help consumers make the right decision about genetic
testing, it is necessary for health care professionals to have
evidence of the validity and utility of a particular test. Of
the 46 DTC genetic testing Web sites, only slightly more
than half (54.3%) offered such information to health care
professionals. With a low prevalence of professionaltargeted information, these Web sites discourage professional participation in the decision-making process.
Although the negative impact can be alleviated by professional genetic counseling, only 39.1 % of the DTC Web
sites offered genetic counseling services, and among these,
only 2 made pretest counseling mandatory. The lack of a
professional intermediary is dangerous for consumer
welfare and may also put a strain on the patient-doctor
relationship.

Results on the Use of Emotional Appeals
Our analysis of genetic testing Web sites suggests that far
from providing only objective information, these Web sites
appeal often to consumers' emotions. A typical positive
emotional appeal is the promise or actual experience
(through user testimonials) of positive outcomes from taking a test. For example, consumers may experience relief,
assurance, and happiness when they receive positive test
results. However, even with the possibility of negative test
results, many Web sites still promoted the positive feeling
of empowerment. The reasoning was that knowing about
heightened risk allows a person to better control or manage
his or her life and health. Negative emotional appeals were
also used. Fear was most often portrayed in the pretest stage
and was often elicited through a family history of a particular disease or through the severity of threat from a disease.
In contrast, regret, guilt, and sadness were associated most
often with potential negative outcomes if a person were not
to take a test. In some cases, negative emotions were copresented with the promise of positive emotions if a person
were to take a test, creating a powerful contrast.
On the use of emotional appeals, our analysis revealed
significant differences between DTC and professional
genetic testing Web sites and between consumer and professional sections within the same DTC Web sites (for the
distribution of total emotional appeals used, see Figure 1).
On average, a DTC Web site used 2.52 emotional appeals,
whereas professional Web sites used an average of .88 emotional appeals (t = 3.77, p < .001). Compared with professional Web sites, DTC Web sites used both more positive
emotional appeals (MoTc = 2.09 versus Mprofessional = .76;
t = 3.95, p < .001) and more negative emotional appeals
(MoTC = .43 versus Mprofessional = .12; t = 2.07, p = .04).
Emotional appeals were also used more in the consumer
section (M = 2.83) than in the professional section (M =
1.25; t = 2.79, p = .008). This significant difference is
attributable mainly to the higher use of positive emotional
appeals (for consumer sections, M = 2.29, and for profes-
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sional sections, M = 1.00; t = 3.33, p = .002). The number
of negative appeals did not differ significantly between the
sections (for consumer sections, M = .54, and for professional sections, M = .25).

Use of Emotional Appeals in OTC Web Sites
The most popular emotional appeals were warmth and
empowerment, both of which were present in 60.9% of
DTC Web sites. This frequent use of an empowerment
appeal is not surprising, because it is the least dependent on
actual test results and therefore is a versatile, persuasive
tool. Even more revealing, the prevalence of an empowerment appeal varied significantly by whether a Web site
allowed consumers to order directly (X2 = 13.81, p = .001).
The appeal was present in 90.0% of the direct-order Web
sites but in only one-third of the non-direct-order Web sites.
By using this popular ploy of appealing to a person's desire
to be in control, the direct-order Web sites may unduly
encourage consumers to take a genetic test without fully
understanding the consequences.
The second most popular positive emotional appeal was
assurance, which was present in 34.8% of DTC Web sites.
Relief appeal, which portrays a sense of relaxation after the
removal of stressful stimuli (e.g., worrying about getting a
disease), was used by 26.1 % of the DTC Web sites, followed by happiness/joy (21.7%). Together, these positive
emotional appeals attempt to engender a positive feeling
toward the advertiser, which may have nothing to do with
what the product actually offers. For example, many Web
sites portray healthy-looking, smiling people in a warm
family setting, implying that genetic testing could bring
about such desirable outcomes. Although the effects of
these emotion-arousing images may seem subtle to a consumer, prior research suggests that feelings engendered by
such messages can powerfully influence consumer attitudes
and purchase intentions (Edell and Burke 1987).
Although the use of negative emotional appeals was less
prevalent in all Web sites, a significant portion (26.1 %) of
DTC Web sites used fear appeals. As a popular advertising
tactic, a fear appeal is designed to alert consumers to a
threatening scenario that leads to a negative consequence.
By arousing the undesirable emotion of fear, these DTC
genetic testing Web sites activate consumers' coping
mechanisms, encourage them to comply with the solutions
offered, and enhance consumers' attitudes toward the products and services offered (LaTour, Snipes, and Bliss 1996).
The second most popular negative emotional appeal was
regret, which was present in 10.9% of DTC Web sites. The
least common emotional appeals were pride (4.3%), sadness (4.3%), and guilt (2.2%).
Use of Emotional Appeals Toward Health Care
Professionals
Although some of the emotional appeals used often by DTC
Web sites (e.g., warmth, assurance) were also more dominant in professional sites, three important DTC emotional
appeals-empowerment (X 2 = 12.00, p = .001), warmth
(X 2 = 4.93, p = .03), and happiness/joy (X2 = 4.39, p =
.04)-were used significantly less by professional Web
sites. Although empowerment was a major ploy in marketing genetic tests to consumers, companies may consider it
ineffective with professionals, who already wield signifi-
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Figure 1.

Distribution of the Number of Emotional Appeals
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cant power. For professional Web sites, warmth and assurance were the most frequently used emotional appeals,
which were present in 29.4% and 23.5% of the Web sites,
respectively. These were followed by empowerment and
relief (both 11.8% ). Of the professional Web sites, 5.9%
used fear and guilt, and none employed the other emotional
appeals (happiness, pride, regret, and sadness). When we
compared the professional and consumer sections within
the same Web sites, a few significant differences emerged.
The professional sections used significantly less happiness/
joy (0% versus 29.2%; 2 = 8.20, p = .004), empowerment
(29.2% versus 54.2%; x2 = 3.09, p = .08), assurance (8.3%
versus 37.5%; x2 = 5.78, p = .02), and relief (12.5% versus
33.3%; 2 = 3.04, p = .08) appeals than the consumer sections. Given that these sections reside within the same Web
sites, such differences in the use of emotional appeals are
astounding. It is apparent that companies deliberately
employ more emotional appeals and present themselves as
compassionate agents when communicating with consumers, potentially augmenting the persuasive power of
their marketing messages.

x

x

Policy Recommendations
Our review of the current state of affairs suggests significant problems with existing practices of DTC marketing of

genetic tests. The current lack of oversight of the genetic
testing industry leaves consumers vulnerable as they strive
to protect their welfare without the knowledge or tools necessary to do so. Oftentimes, such a failure to enact specific
regulations can have a significant impact on social policy
because its absence allows other forces to shape practices
and policies; for example, as Clayton (2004) points out,
litigation against physicians, rather than legislation, led to
the inclusion of genetic testing in routine prenatal care.
Although many view routine prenatal testing as a good
thing, some drawbacks have been observed. For example,
test results can put some women in the difficult position of
having to decide whether to continue a pregnancy. Some
critics of the practice have also noted that the availability of
prenatal testing has altered society's view of children born
with genetic diseases-that is, that they should not have
been born. Furthermore, instead of viewing the birth of an
impaired child as an unfortunate roll of the genetic dice,
women are viewed as blameworthy for failing to prevent it.
The situation with prenatal care reveals the potential
negative outcomes of policy creation through inaction.
Although the exact effects of DTC marketing of genetic
tests remain to be seen, we advocate proactive public policy
aimed at preventing negative outcomes rather than reactive
regulations aimed at addressing negative outcomes after
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they have happened. Specifically, on the basis of our
review, we recommend a three-pronged approach to public
policy in this area: consumer education, physician intervention and education, and regulation of marketing activities.

Consumer Education
I~ discussing consumer vulnerability in the marketplace,
Rmgold (2005) recognizes the importance of education in
reducing vulnerability. We concur and recommend a wellpublicized campaign to educate consumers about the risks
and benefits of genetic testing and to increase awareness of
existing resources that provide information about genetic
tests, such as the FTC Web site's concise and helpful
brochure titled "At-Horne Genetic Tests: A Healthy Dose
of Skepticism May Be the Best Prescription" (see http://
www.ftc.gov/bcp/edu/pubs/consurner/health/hea02.shtrn).
The American Academy of Family Physicians also has an
informative Web site on this topic (see http://farnilydoctor.
org/online/farndocen/horne/healthy/prevention/462.htrnl).
We propose that a public health campaign use traditional
mass media to ensure sufficient reach to the public. The
goals of the campaign would be (1) to increase awareness
of the complexities of genetic tests and consumers' lack of
knowledge in this area, (2) to encourage consumers to seek
more information in their decision making, and (3) to publicize quality information currently available in this area. The
campaign should also involve industry and professional
organizations to draw on their expertise and existing
resources. We believe that the industry should be motivated
to participate in such a campaign because it may also raise
awareness of genetic tests.
This consumer education campaign should work in conj~nction with DTC marketing from genetic testing cornpames. Research on DTC advertising of prescription drugs
shows that consumers are likely to seek information after
seeing a DTC advertisement (Calfee 2002; Liu et al. 2005).
It is reas_onable to expect that exposure to DTC marketing
of genetic tests may lead to similar behavior. This postexposure information seeking is a crucial juncture because
it can potentially remedy the deficiency in DTC marketing
and help consumers make the right decision. In an effort
to direct information seeking to the right sources, public
education campaigns could be timed to coincide with DTC
marketing campaigns. Public education materials from
un~iased s_o~rces could be distributed to patients through
their phys1c1ans during patient consultation sessions that
may result from DTC marketing campaigns. Because the
Internet is a crucial source for health care information
genetic testing companies should also be encouraged to link
to these public education materials from their Web sites.
The ultimate goal of public education is to increase con~urners' k?owledge, to empower them, and, effectively, to
produce mformed decision makers" (Andrews et al. 1994,
p. 196).

Physician Intervention and Education
Public education alone is unlikely to produce sufficient
knowledge for an average consumer to make sound deci~ions about ge?etic_ testing. Physicians will likely play an
important role m this area. In a study of consumer inforrna-
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tion seeking after exposure to DTC advertising of prescription drugs, Liu and colleagues (2005) show that despite
consumers' stated intentions, they ultimately sought physician consultation about drugs they had seen advertised.
Although consumers intended to use the Internet as a substitute, it ended up being a supplement rather than a
replacement. Because physicians are also likely to be key
players in genetic testing, it is important to clarify their role
in this process and to educate and prepare them for the
genomic era.

Physician Intervention
In formulating public policy in this area, useful guidance
can be drawn from the distinction between prescription and
over-the-counter drugs. Currently, the FDA can approve a
change in a drug's status from prescription-only to overthe-counter if its benefits have been proved to outweigh its
risks, if consumers can self-diagnose their conditions and
easily understand the drug's label, and if the potential for
abuse is low (Cohen, Paquette, and Cairns 2005; Jacobs
1998). These rules imply that it may be too soon to allow
"over-the-counter genetic tests." Although the effects of
genetic tests vary from the side effects of prescription
drugs? uncertainty about the consequences of undergoing
genetic tests makes it inappropriate to assume that the benefits w_ill outweigh the risks. Furthermore, although genetic
test kit labels can be made relatively accessible, a key step
in "consuming" genetic tests is the interpretation of test
results, which is much trickier for the average consumer.
The probabilistic nature of genetics and many other factors
that affect a consumer's health condition make accurate
self-diagnosis and determination of an appropriate course of
treatment difficult. Thus, genetic self-tests at this time
would fail to meet classification criteria similar to those
used to designate drugs as over-the-counter.
~or these reasons, we recommend that predictive genetic
testmg be offered only through a physician intermediary
and t~at patients be discouraged from undergoing genetic
tests m the absence of indications that it would be useful
(~-_g., !amily history, clinical symptoms). When clinical justification for a genetic test is lacking but the patient's desire
for it is present, the physician should warn the patient of
"the possibility of psychological stress induced by knowledge _that the test will reveal" (Bayley 2004, p. 183). This
warnmg_s~~uld accompan~ ~he usual information regarding
t~e poss1b1hty of false-pos1t1ve, false-negative, or inconcluSIVe results, as well as about the likely clinical and personal
value of the test for the patient. Moreover, patients should
be warned that even if a positive result is later disconfirmed, the initial positive result might cause short- or longterm psychological distress. In agreement with Munson
(2007), however, we acknowledge that a test's lack of clinical value does not mean that its results are of no value to
the pati~nt; there may be defensible reasons for undergoing
a genetic test even if it does not facilitate prevention or
treatment of a disease. For this reason, we recommend a
prohibition on DTC marketing of genetic tests that lack
analytic or clinical validity, but we withhold such a recommendation for tests that merely lack clinical utility.
Although our recommendation is more restrictive than
the recent American Society of Human Genetics statement
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(Hudson et al. 2007), our decision is based on the current
lack of other protections that are in place. In the future, as
more data on the effects of genetic tests on consumer health
and welfare become available, we may alter this conclusion.
Eventually, over-the-counter-like status for some genetic
tests may be reasonable, but a clear guideline for conversion must first be established. The guideline must consider
the test's analytical and clinical validity, the prevalence and
nature of the target disease, and whether test results will
prompt consumers to alter their behavior and how. Along
these lines, Javitt (2007, p. 646) proposes "a tiered
approach that matches the level of risk to the degree of
[FDA] oversight"; that is, the regulatory focus should not
be on whether the test is a laboratory-developed test or is
sold as a kit (Javitt 2007; Katsanis, Javitt, and Hudson
2008).
Initially, it might be expected that genetic testing companies would resist the physician intervention requirement,
but self-interest may dictate their support for such a move.
In Pines' s ( 1999) discussion of DTC marketing of prescription drugs, he notes that pharmaceutical companies have
often employed the "learned intermediary" defense, claiming that they are clear of liability because the use of the
drug is controlled not by the pharmaceutical companies but
by the health care professionals whose duty is to inform the
patient regarding risks, benefits, and proper use of the drug.
Using Perez v. Wyeth as an example, 5 Pines (1999, p. 515)
notes that DTC advertising "alters the calculus of the
learned intermediary [such that] the learned intermediary
doctrine 'does not apply to direct marketing of drugs to
consumers."' Consequently, in the interest of protecting
themselves from potential legal liability, genetic testing
companies may welcome physicians as gatekeepers and
refrain from DTC selling.

Physician Education
Although there are good reasons physicians may favor their
role as gatekeepers (e.g., better management of relationship
with patients, protection of consumer welfare, increased
revenue), existing evidence shows that physicians-primary care physicians, in particular-are still somewhat
reluctant to integrate genetic testing into their practices
(Bayley 2004). This may be partially due to their current
lack of knowledge of genetics and an accompanying lack of
confidence in handling requests for genetic tests or interpreting test results. Although medical schools are improving genetics education, many physicians currently practicing medicine received inadequate training in clinical
genetics; thus, many on the front line are unprepared to deal
with patients' inquiries about genetic testing (Bayley 2004).
To address this issue, significant improvements in genetics
education in medical schools, residency programs, and continuing medical education programs are necessary. The
National Coalition for Health Professional Education in
Genetics is currently working to improve physician knowledge of genetics. This group has recently created a CD
titled Genetics and Common Disorders: Implications for
Primary Care and Public Health Providers, which can be

5Saray Perez v. Wyeth Labs., Inc., 734 A. 2d 1245 (N.J. 1999).

obtained for free through the Internet and used for educational purposes. With the rapid advances in genetic medicine and a new interest in its possible role in preventive
care, physicians will likely welcome educational programs
that help them function more effectively.

Regulation of OTC Marketing of Genetic Tests
Regulation of DTC marketing of genetic tests must address
quality control and content of marketing communication. In
terms of quality control, in accordance with the recommendations of the National Institutes of Health Task Force on
Genetic Testing ( 1997) and Munson (2007), we propose a
prohibition on offering to the public any genetic test that is
not analytically valid. Furthermore, we recommend that
either the FDA or the CMS publish a clear and accessible
list of analytically and clinically valid tests and widely publicize its existence so that both providers and laypersons
can easily determine whether the test they intend to use has
been shown to be accurate. We agree with Javitt's (2007, p.
647) recommendation that the FDA and CMS jointly
develop a "guidance document outlining the type of data
required to support [a claim of] clinical validity." Furthermore, a link to this resource should be included in the standard information section that we propose should be
included in every DTC genetic testing Web site. Exposing
consumers to this list would help correct the mistaken belief
that all genetic tests on the market are FDA approved or
scientifically valid (Donohue, Cevasco, and Rosenthal
2007; Javitt 2007). We also recommend that the CMS provide a clear and accessible resource for determining
whether labs conducting genetic tests are qualified to do so.
Regarding the content of DTC marketing communication, we recommend that more specific guidelines be
devised for genetic tests and that, in agreement with Javitt
(2007) and Katsansis, Javitt, and Hudson (2008), FDA and
FTC enforcement of existing prohibitions against misleading advertisements be intensified. Beyond the truthful
advertising and fairness principles governing all advertisements, regulation of marketing communications in this area
needs to consider the intricate nature of genetic tests and
their far-reaching effects on consumer health and social
welfare. Although the FDA regulation of DTC advertising
of prescription drugs may be a useful guide in formulating
policy in this area, its limitations, such as the lack of clarity
and its inadequate consideration of laypersons (Pines 1999),
must also be acknowledged and addressed. Minimally, we
recommend that all DTC marketing materials specify the
potential harms of a test, point out the probabilistic nature
of genetics, and provide indicators of test accuracy and
utility.

Internet-Specific Issues
According to a PEW Internet & American Life study, only
15% of online health information seekers examined the
source and date of online resources (Fox 2006), leaving
most consumers vulnerable to incorrect and low-quality
information. These findings, together with our analysis,
suggest a need to regulate online marketing materials.
Although the FTC (2000) has specified that its laws are not
media specific and thus apply to the Internet, regulations of
online genetic test marketing need to address at least two
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unique issues: presentation of information and linking to
external information.

Presentation of Information
A unique aspect of online resources is the often-complex
navigational structure of Internet sites, which makes them
trickier to regulate than traditional advertisements. This
raises two issues. First, the amount of space available on the
Internet enables a Web site to offer far more information
than traditional marketing media. However, increased quantity provides no assurance of good quality. As a Journal of
the American Medical Association editorial notes, "The
problem is not too little information but too much, vast
chunks of it incomplete, misleading, or inaccurate" (Silberg, Lundberg, and Musacchio 1997, p. 1244). Genetic
science is complex even in small doses, and in any case of
information overload, comprehension of the material can be
lost. Second, Web site content is not always presented in a
way that promotes sound decision making. As the FTC
(2000) points out, companies sometimes present critical
information, such as disclosures, in such a way that it is easily overlooked by consumers. During our analysis, we often
needed to drill down deep into a Web site to find certain
information. Given the more casual nature of most consumers' information searches, there is reason to doubt that
consumers will find the information needed to make
informed decisions.
To address these issues, we recommend that a standard
section be included in every DTC genetic testing Web site.
The information in this section should be written in layman's terms so that an average consumer can easily understand it. A link to this standard section should be prominently displayed on every page within the Web site for easy
access. Standardized icons can also be created to identify
information in the section so that consumers can easily
compare multiple DTC Web sites. The goal of this standard
section is to offer objective, accessible information to help
consumers make prudent decisions about whether to
undergo a certain test.
We expect that the presence/absence of this standard section could function as a starting point for creating an online
list of FTC-compliant and noncompliant companies.
Although enforcing regulations in an online environment is
likely to be significantly more challenging than in the
bricks-and-mortar context, the 24-7 public availability of
online materials makes it considerably easier to monitor
Web sites for compliance. The new mentality of consumer
participation and collaboration in the newer generation Web
may propel grassroots-level monitoring (Tapscott and
Williams 2006). If the FTC lacks the resources to conduct
all the monitoring itself, other interested groups or individuals may do so on a volunteer basis after the FTC clearly
establishes the compliance criteria.

Linking to External Information
New regulations should also specify firms' obligations and
liability for external information linked from their Web
sites. Many of the genetic testing sites we analyzed contained convenient links to information from third-party
sources, some of which functioned as endorsements for the
products or services marketed by the referring site. Such
information can have a persuasive effect in favor of the
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referring site; yet in the current regulatory climate, it is
unclear under what conditions firms are held responsible
for hyperlinked information. As a result, it has been suggested that companies can reduce liability by linking to the
external source's home page rather than to a specific page
within that external site and by displaying explicit disclaimers before consumers navigate to the external Web site
(Heather 2001). Although these measures may diminish liability, they do not necessarily reduce the persuasive effect
of such information on consumers. We recommend creating
specific guidelines that will close such loopholes and thus
protect consumers.
In his work on online marketing of prescription drugs,
Heather (2001) suggests that the treatment of hyperlinked
external information from pharmaceutical companies' Web
sites can be partially borrowed from guidelines used in the
investment community. Specifically, the Securities and
Exchange Commission (2000) considers three factors when
determining liability for hyperlinked information: ( 1) context of the link, such as whether the referring site explicitly
endorses the external information; (2) risk of confusion by
users about information sources; and (3) presentation of the
linked information, such as the actual external page that is
linked to and the layout of the link in the referring site.
Similar guidelines can be issued on how hyperlinked information from genetic testing companies' Web sites should
be treated.

Resource Considerations
In recommending more stringent regulations, we acknowledge the necessary costs that come with implementing such
regulations. Currently, FDA staff and other resources are
limited. However, in the interest of protecting public health,
conserving individual and collective health care resources,
and preserving the present and future credibility of genomic
science, Congress should give greater priority to providing
adequate funding for oversight and regulation of genetic
tests. This is especially critical given the likely expansion of
the role of genetics in twenty-first-century health care.
In the meantime, creative solutions can be used to draw
available resources from various entities and, thus, to lessen
the burden on one particular agency. Here, we offer a few
possibilities. First, as we mentioned previously, the CMS
has moved toward establishing a specialty area for genetic
testing. Given the rapid development of the field, reconsidering such a specialty area may constitute a quick and efficient solution because some preparation may have been
done previously in anticipation of establishing the area.
Second, in addition to government agencies, it may be
desirable to appeal to the prudential interests of companies
that market their tests directly to consumers. However, this
strategy is unlikely to be effective in all cases. Therefore, it
may be necessary to align the interests of these companies
with public welfare in other ways. For example, it is in
insurance companies' long-term interest to pay only for
tests that are analytically and clinically valid because only
such tests are likely to lead to long-term health benefits.
This may discourage genetic testing service providers from
marketing bogus genetic tests because such tests will incur
out-of-pocket expenses and thus put the marketer at a
competitive disadvantage. Finally, as we discussed in the
preceding section, the open nature of the Internet facilitates
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collaborative citizen efforts in implementing regulation
through this medium. This involvement of civil and trade
organizations can further lessen the burden on limited federal resources.

Further Research
In this study, we assessed the status of DTC marketing of
genetic tests and regulations in this area. Our analysis
revealed that current business practices are problematic and
that existing public policy has largely neglected to address
these problems. Combined with consumers' lack of knowledge, this is an undesirable situation. Consequently, we
issue a call to marketing and ethics scholars to contribute to
a sound genetic testing marketplace through continued
inquiry into the impact of genetic tests and the DTC marketing of such tests on individual consumers and society as
a whole. A few topics deserve special attention.
First, although this research assesses current business
practices, our understanding is incomplete without knowledge of how consumers respond to these marketing messages. Can consumers process these messages and discern
misleading information? How and to what extent does
information from DTC marketing sources affect consumers' decision making? More generally, how do genetic
test results alter consumers' health-related decision making? Consumer information-processing and decisionmaking theories, especially as they relate to consumer
knowledge (e.g., Alba and Hutchinson 2000), will prove
useful in answering these questions. Furthermore, recent
research shows that both the content and the design of a
DTC Web site can affect consumer information processing
and attitudes (Sewak et al. 2005). In this research, with the
exception of emotional appeals, we focused primarily on
the informational aspect of DTC Web sites. This can be
extended in the future to include executional elements of a
Web site. Further research should also include a more indepth examination of the quality of information provided
on genetic testing Web sites.
Second, further research should focus on health care professionals. With the extensive impact of genetic sciences on
the health care industry, the ready availability of genetic
tests to consumers is bound to affect the nature of patient
care. Related to our policy recommendations, it is necessary
to better understand physicians' knowledge of and attitude
toward genetic tests. Researchers should also examine the
marketing of genetic tests targeted specifically toward
health care professionals to determine its impact on their
knowledge, judgment, and practices. Moreover, similar to
studies of DTC advertising of prescription drugs,
researchers should examine the impact of DTC marketing
of genetic tests on patient-physician relationship. It would
be particularly worthwhile to examine the potential interaction between DTC marketing and professional-targeted
marketing on patient-physician relationship and on market
outcomes. Research in these areas would enable a more
accurate assessment of the impact of DTC marketing of
genetic tests on public health and consumer welfare.
Third, further research could also address the impact of
expanded genetic testing on the practice of informed consent. The many unknowns in clinical genetics call into
question the very possibility of informed consent as tradi-

tionally construed. Will the expansion of genetic testing
require the retooling of informed consent requirements?
Does the emphasis on individual autonomy, so prominent in
U.S. bioethics and medical practice, make sense when faced
with complex genetic information? Although we recommend improved education of the public and increased
awareness of the need for scrutiny of claims about genetic
tests, it is doubtful that the extent of transformation of the
public will render guidance from genetic professionals
unnecessary. The current emphasis on individual autonomy
and "value-neutral" genetic counseling, which some have
already begun to question, will become more problematic to
sustain in the face of complex genetic information and the
decisions that will be based on it.
Finally, an inquiry into the impact of DTC access to
genetic tests on particular groups would be an important
area for further research. Along these lines, De MeloMartin (2006a) cautions against ignoring the social contexts
in which people must decide whether to undergo genetic
testing, at the risk of reinforcing and perpetuating injustices
against vulnerable or underprivileged groups. This includes
consideration of, for example, access to resources that will
be needed by those who undergo genetic testing. Policy
makers should work to narrow gaps between DTC access to
genetic tests and the means to treat or prevent the problems
revealed or predicted by these tests. It is already the case
that women's experience with genetic tests and any accompanying burdens is, for various reasons, greater than that
of most men (De Melo-Martin 2006a). Thus, it would be
important to examine the distribution of benefits and burdens of genetic testing across gender and socioeconomic
lines and formulate means of amending any inequitable
distribution.
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